Investors focused on the Medical space have likely heard of Taro Pharmaceutical Industries , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Taro Pharmaceutical Industries is a member of our Medical group, which includes 763 different companies and currently sits at #12 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. TARO is currently sporting a Zacks Rank of #2 (Buy).

Over the past three months, the Zacks Consensus Estimate for TARO's full-year earnings has moved 13.10% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

According to our latest data, TARO has moved about 14.11% on a year-to-date basis. In comparison, Medical companies have returned an average of 2.24%. This means that Taro Pharmaceutical Industries is performing better than its sector in terms of year-to-date returns.

Breaking things down more, TARO is a member of the Medical - Drugs industry, which includes 163 individual companies and currently sits at #105 in the Zacks Industry Rank. This group has gained an average of 7.84% so far this year, so TARO is performing better in this area.

Investors with an interest in Medical stocks should continue to track TARO. The stock will be looking to continue its solid performance.